




# Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial

Philippe Montravers<sup>1,18\*</sup> , Florence Tubach<sup>2</sup>, Thomas Lescot<sup>3</sup>, Benoit Veber<sup>4</sup>, Marina Esposito-Farèse<sup>5</sup>, Philippe Seguin<sup>6</sup>, Catherine Paugam<sup>7</sup>, Alain Lepape<sup>8</sup>, Claude Meistelman<sup>9</sup>, Joel Cousson<sup>10</sup>, Antoine Tesniere<sup>11</sup>, Gaetan Planteveve<sup>12</sup>, Gilles Blasco<sup>13</sup>, Karim Asehnoun<sup>14</sup>, Samir Jaber<sup>15</sup>, Sigismond Lasocki<sup>16</sup>, Herve Dupont<sup>17</sup> and For the DURAPOP Trial Group

© 2018 Springer-Verlag GmbH Germany, part of Springer Nature and ESICM

*Intensive Care Med (2018) 44:300–310*

2018.07.10

慈恵ICU Journal Club

大谷さゆみ